# Optimal Timing of Ketamine Initiation for SCD Pain

> **NCT07450430** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Boston Children's Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Crisis

## Interventions

- **DRUG:** Ketamine hydrochloride injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07450430
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2029-02
- **Final completion:** 2030-02
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07450430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07450430, "Optimal Timing of Ketamine Initiation for SCD Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07450430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*